ArticleNeurology and therapy2024

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.

Malaz Boustani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.